A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group.
Abstract | BACKGROUND:
Carboplatin is an analogue of cisplatin with less nonhematologic toxicity than the parent compound. It has been demonstrated previously to have activity against a spectrum of pediatric brain tumors. This Phase II study was undertaken to assess the activity of carboplatin in children with various solid tumors. METHODS: RESULTS: A complete response was seen in 1 of 15 evaluable patients with Ewing's sarcoma. Partial responses were seen in 2 of 17 evaluable patients with neuroblastoma, 1 of 16 with soft tissue sarcoma, 2 of 5 with Wilms' tumor, and 1 with an endodermal sinus tumor of the testis. Objective responses were not seen in patients with malignant lymphoma, osteosarcoma, or hepatoma. Four of 7 patients who responded to carboplatin had previously received cisplatin. Sixty-two percent of patients had a platelet count nadir of less than 50,000/mm3, and 41% had an absolute neutrophil count nadir of less than 1,000/mm3. Ototoxicity, nephrotoxicity, hypomagnesemia, hypertransaminasemia, and nausea and vomiting each were seen in fewer than 10% of patients. CONCLUSIONS:
|
Authors | L J Ettinger, P S Gaynon, M D Krailo, N Ru, E S Baum, S E Siegel, G D Hammond |
Journal | Cancer
(Cancer)
Vol. 73
Issue 4
Pg. 1297-301
(Feb 15 1994)
ISSN: 0008-543X [Print] United States |
PMID | 8313334
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Carboplatin
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Female
- Humans
- Infant
- Lymphoma
(drug therapy)
- Male
- Neoplasms
(drug therapy)
- Recurrence
- Salvage Therapy
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|